Cancer examination method and cancer treatment agent

JPWO2022114091A5Pending Publication Date: 2024-12-04
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022565427
Authority / Receiving Office
JP · JP
Patent Type
Applications
Priority Date
2021-11-26
Filing Date
2021-11-26
Publication Date
2024-12-04

AI Technical Summary

Technical Problem

Accurate cancer diagnosis and prognosis remain challenging, particularly for lung adenocarcinoma patients, where existing methods fail to reliably predict recurrence rates and survival outcomes based on SGLT1 and SGLT2 expression levels.

Method used

A method involving the detection of SGLT1 and SGLT2 expression in cancer tissues to predict patient prognosis, where positive SGLT1 expression indicates a good prognosis and positive SGLT2 expression indicates a poor prognosis, with specific thresholds determining the ratio of positive cells to cancer cells, and consideration of diabetic status and EGFR mutations for more accurate predictions.

Benefits of technology

This method provides a reliable means to predict recurrence rates and survival outcomes for lung adenocarcinoma patients, enabling targeted treatment approaches by distinguishing between good and poor prognoses based on SGLT1 and SGLT2 expression levels.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a method for predicting the prognosis of patients with lung adenocarcinoma. The present invention relates to a method for predicting the prognosis after cancer removal of patients with lung adenocarcinoma. The present invention also relates to a method for treating patients with lung adenocarcinoma.
Need to check novelty before this filing date? Find Prior Art

Description

Cancer testing method and cancer treatment drug

[0001] The present invention relates to a method for testing for cancer and a cancer therapeutic agent.

[0002] In 2018, the number of deaths from cancer in Japan was 1.36 million, of which 370,000 (27%) were cancer-related. In addition, 980,000 new cases of cancer were diagnosed in 2018, making accurate cancer diagnosis a societal challenge.

[0003] Non-Patent Document 1 confirms the mRNA expression of SGLT1 and SGLT2 and discloses that there is no difference in expression between lung cancer and normal lung tissue. It discloses that SGLT2 is highly expressed in relation to metastasis and plays a role in glucose uptake. Non-Patent Document 2 discloses that tissues containing a large amount of lung adenocarcinoma were evaluated and that SGLT2 mRNA expression was high in cancer patients. Non-Patent Document 3 discloses that there is no difference in SGLT1 expression in lung cancer. Non-Patent Document 4 discloses that SGLT2 is highly expressed in pre-malignant and early / low-grade lung adenocarcinoma.

[0004] Ishikawa N. et al., Jpn. J. Cancer Res., 92, 874-879, 2001Zhang X., et al., International Journal of Oncology, 54, 199-208, 2019Madunic IV et al., Arh. Hig. Rada. Toksikol., 69, 278-285, 2018Scafoglio CR et al., Sci. Transl. Med., 10, 467, 2018

[0005] The present invention provides a method for testing for cancer and a cancer therapeutic drug.

[0006] The present inventors have found that the prognosis of a patient after cancer resection can be predicted based on the expression of SGLT family genes in the resected cancer tissue.

[0007] The present invention provides, for example, the following inventions. [1] A method for predicting the prognosis of a cancer patient, comprising: (1) a detection step of detecting the expression of either or both of SGLT1 and SGLT2 in cancer tissue obtained from the cancer patient {wherein positive SGLT1 expression in the cancer tissue indicates a good prognosis, and positive SGLT2 expression in the cancer tissue indicates a poor prognosis}, or (2) a step of predicting a good prognosis if the patient is a diabetic patient and a poor prognosis if the patient is a non-diabetic patient. [2] The method described in [1] above, wherein the cancer patient is a lung adenocarcinoma patient. [3] The method described in [1] or [2] above, wherein the cancer patient has undergone cancer resection surgery. [4] The method described in any of [1] to [3] above, wherein the level of expression is determined based on the ratio of positive cells to cancer cells. [5] The method described in any of [1] to [4] above, wherein the expression is protein expression. [6] The method of any of [1] to [5] above, wherein the detection step comprises detecting SGLT1 expression. [7] The method of any of [1] to [6] above, wherein the detection step comprises detecting SGLT2 expression. [8] The method of any of [1] to [7] above, wherein the prognosis is at least one selected from the group consisting of recurrence rate and survival rate. [9] The method of any of [1] to [8] above, comprising both (1) and (2) above, and further comprising either or both of: (a) predicting a good prognosis for the patient if the patient is a diabetic patient and SGLT1 expression is positive and / or SGLT2 expression is negative; and (b) predicting a poor prognosis for the patient if the patient is a non-diabetic patient and SGLT1 expression is positive / negative and / or SGLT2 expression is positive.

[10] The method of any of [1] to [9] above, wherein the lung adenocarcinoma is an early stage cancer selected from the group consisting of stage I and II.

[11] A pharmaceutical composition comprising an SGLT2 inhibitor for use in treating lung adenocarcinoma in patients with positive SGLT2 expression.

[12] The pharmaceutical composition of the above-mentioned

[11] , wherein the patient is a patient predicted to have a poor prognosis by the method of any one of the above-mentioned [1] to

[10] .

[13] The pharmaceutical composition of the above-mentioned

[11] , wherein the patient is a lung adenocarcinoma patient who also has diabetes.

[14] The pharmaceutical composition of the above-mentioned

[11] or

[13] , wherein the patient further has positive SGLT1 expression.

[15] The pharmaceutical composition of any one of the above-mentioned

[11] to

[13] , wherein the patient has negative SGLT1 expression.

[0008] [1A] A method for predicting the prognosis of a cancer patient, comprising a step of detecting expression of SGLT2 protein in lung adenocarcinoma tissue obtained from the patient (wherein negative SGLT2 expression in the cancer tissue indicates a good prognosis, or positive SGLT2 expression indicates a poor prognosis). [2A] The method according to [1A], wherein the cancer patient has undergone cancer resection surgery. [3A] The method according to [1A] or [2A], wherein whether the expression is positive or negative is determined based on the ratio of positive cells to cancer cells. [4A] The method according to any one of [1A] to [3A], further comprising predicting a good prognosis if the patient has a mutation in epidermal growth factor receptor (EGFR), and predicting a poor prognosis if the patient does not have a mutation in EGFR. [5A] The method according to any one of [1A] to [4A], wherein the prognosis is at least one selected from the group consisting of recurrence rate and survival rate. [6A] The method of any one of [1A] to [5A], further comprising determining whether the patient is a diabetic patient, wherein (a) if the patient is a diabetic patient and SGLT2 expression is negative, the patient's prognosis is indicated to be good, or (b) if the patient is a non-diabetic patient and SGLT2 expression is positive, the patient's prognosis is indicated to be poor. [7A] The method of any one of [1A] to [6A], wherein the lung adenocarcinoma is an early stage cancer selected from the group consisting of stages I and II. [8A] A pharmaceutical composition comprising an SGLT2 inhibitor for use in treating lung adenocarcinoma in an SGLT2-positive patient {wherein, in a preferred embodiment, the patient may be a patient predicted to have a poor prognosis by the method of any one of [1A] to [7A]}. [9A] The pharmaceutical composition of [8A], wherein the patient is a diabetic, SGLT2-positive patient. [10A] The pharmaceutical composition of [8A], wherein the patient is a SGLT2-positive, non-diabetic patient.

[0009] [11A] A method for predicting the prognosis of a lung adenocarcinoma patient, comprising a step of detecting SGLT1 expression in lung adenocarcinoma tissue obtained from the lung adenocarcinoma patient {wherein positive SGLT1 expression in the cancer tissue indicates a good prognosis or a possible good prognosis, or negative SGLT1 expression indicates a poor prognosis or a possible bad prognosis}. [12A] The method according to [11A], further comprising a step of detecting SGLT2 expression in the lung adenocarcinoma tissue {wherein positive SGLT1 expression and negative SGLT2 expression in the cancer tissue indicates a good prognosis or a possible good prognosis, or negative SGLT1 expression and positive SGLT2 expression in the cancer tissue indicates a poor prognosis or a possible bad prognosis}. [13A] The method according to [11A] or [12A], wherein the cancer patient is a patient who has undergone cancer resection surgery. [14A] The method of any one of [11A] to [13A], wherein whether the expression is positive or negative is determined based on the ratio of positive cells to cancer cells. [15A] The method of any one of [11A] to [14A], wherein the expression is protein expression. [16A] The method of any one of [11A] to [15A], wherein the prognosis is at least one selected from the group consisting of recurrence rate and survival rate.

[17] The method of any one of [11A] to [16A], further comprising determining whether the patient is a diabetic patient, wherein (a) if the patient is a diabetic patient and SGLT1 expression is positive, the prognosis of the patient is good or likely to be good, or (b) if the patient is a non-diabetic patient and SGLT1 expression is negative, the prognosis of the patient is bad or likely to be bad. [18A] The method of any one of [11A] to [17A], wherein the lung adenocarcinoma is an early stage cancer selected from the group consisting of stage I and II.

[0010] [19A] A pharmaceutical composition comprising an insulin sensitizer for use in treating a subject with diabetes and lung adenocarcinoma. [20A] The pharmaceutical composition of [19A], wherein the insulin sensitizer is one or more selected from the group consisting of biguanides and thiazolidinediones (thiazolidinediones or glitazones). [21A] A pharmaceutical composition comprising an SGLT2 inhibitor in combination with an insulin sensitizer for use in treating a subject with diabetes and lung adenocarcinoma. [22A] A pharmaceutical composition comprising an SGLT2 inhibitor for use in treating a subject with diabetes and lung adenocarcinoma who has been treated or is scheduled to be treated with an insulin sensitizer. [23A] A pharmaceutical composition comprising an insulin sensitizer in combination with an SGLT2 inhibitor for use in treating a subject with diabetes and lung adenocarcinoma. [24A] A combination product comprising an SGLT2 inhibitor and an insulin sensitizer for use in treating a subject with diabetes and lung adenocarcinoma.

[0011] Figure 1 shows recurrence-free survival curves (DFI) for 102 cases of lung adenocarcinoma. A comparison is made between the stage I group and other groups. Figure 2 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. A comparison is made between the stage I and II groups and other groups. Figure 3 shows survival curves for 102 cases of lung adenocarcinoma. A comparison is made between the stage I group and other groups. Figure 4 shows survival curves for 102 cases of lung adenocarcinoma. A comparison is made between the stage I and II groups and other groups. Figure 5 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. A comparison is made between groups based on the ratio of SGLT1-expressing cells to cancer cells. The threshold is 10%. Figure 6 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. A comparison is made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 10%. Figure 7 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 20%. Figure 8 shows survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT1-expressing cells to cancer cells. The threshold is 10%. Figure 9 shows survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 10%. Figure 10 shows survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 20%. Figure 11 shows recurrence-free survival curves for stage I lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT1-expressing cells to cancer cells. The threshold is 10%. Figure 12 shows recurrence-free survival curves for stage I lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 10%. Figure 13 shows recurrence-free survival curves for stage I lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 20%. Figure 14 shows survival curves for stage I lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT1-expressing cells to cancer cells. The threshold is 10%. Figure 15 shows survival curves for stage I lung adenocarcinoma.Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 10%. Figure 16 shows survival curves for stage I lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 20%. Figure 17 shows recurrence-free survival curves for stage I and II lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT1-expressing cells to cancer cells. The threshold is 10%. Figure 18 shows recurrence-free survival curves for stage I and II lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 10%. Figure 19 shows recurrence-free survival curves for stage I and II lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 20%. Figure 20 shows survival curves for stage I and II lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT1-expressing cells to cancer cells. The threshold is 10%. Figure 21 shows survival curves for stage I and II lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 10%. Figure 22 shows survival curves for stage I and II lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 20%. Figure 23 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. A comparison is made between a group aged 70 years or older and other groups. Figure 24 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. A comparison is made between four groups classified according to whether the patient is aged 70 years or older and whether the patient is SGLT1-positive (threshold: 10%). Figure 25 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether the patient is 70 years of age or older and whether SGLT2 is positive (threshold: 10%). Figure 26 shows survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether the patient is 70 years of age or older and whether SGLT1 is positive (threshold: 10%). Figure 27 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. A comparison is made between a diabetic patient group and other groups. Figure 28 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma.Comparisons are made between four groups classified according to whether or not the patient is a diabetic patient and whether or not the patient is SGLT1 positive (threshold: 10%). Figure 29 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether or not the patient is a diabetic patient and whether or not the patient is SGLT2 positive (threshold: 10%). Figure 30 shows survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between the diabetic group and other groups. Figure 31 shows survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether or not the patient is a diabetic patient and whether or not the patient is SGLT1 positive (threshold: 10%). Figure 32 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether or not the patient is a diabetic patient and whether or not the patient is SGLT1 positive (threshold: 10%). Figure 33 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether the CEA level is high (0.5 ng / mL or higher) and whether the patient is SGLT2 positive (threshold: 10%). Figure 34 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether the CEA level is high (0.5 ng / mL or higher) and whether the patient is SGLT2 positive (threshold: 20%). Figure 35 shows survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether the CEA level is high (0.5 ng / mL or higher) and whether the patient is SGLT1 positive (threshold: 10%). Figure 36 shows survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether the CEA level is high (0.5 ng / mL or higher) and whether the SGLT2 level is positive (threshold: 10%). Figure 37 shows survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether the CEA level is high (0.5 ng / mL or higher) and whether the SGLT2 level is positive (threshold: 20%). Figure 38 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between four groups classified according to whether the SGLT1 level is positive (threshold: 10%) and whether the SGLT2 level is positive (threshold: 10%). Figure 39 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma.Comparisons are made between four groups classified according to whether or not SGLT1 is positive (threshold: 10%) and whether or not SGLT2 is positive (threshold: 20%). Figure 40 shows survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT1-expressing cells to cancer cells. The threshold is 10%. Figure 41 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 10%. Figure 42 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. Comparisons are made between groups based on the ratio of SGLT2-expressing cells to cancer cells. The threshold is 20%. Figure 43 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. A comparison is made between a diabetic patient group and other groups. Figure 44 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. A comparison is made between a group with EGFR mutations and a group without EGFR mutations. Figure 45 shows recurrence-free survival curves for 102 cases of lung adenocarcinoma. A comparison is made between diabetic patients and non-diabetic patients. Figure 46 shows survival curves for 102 cases of lung adenocarcinoma. A comparison is made between diabetic patients and non-diabetic patients. Figure 47 shows recurrence-free survival curves for stage I and II lung adenocarcinoma. A comparison is made between diabetic patients and non-diabetic patients. Figure 48 shows survival curves for stage I and II lung adenocarcinoma. A comparison is made between diabetic patients and non-diabetic patients. Figure 49 shows the impact of diabetes on the survival rate of lung cancer patients. Figure 50 shows the impact of diabetes on the recurrence-free survival period of lung cancer patients. Figure 51 shows the impact of diabetes on the survival rate of small cell lung cancer patients. Figure 52 shows the impact of diabetes on the survival rate of small cell lung cancer patients after surgical treatment. Figure 53 shows the impact of diabetes treatment on recurrence-free survival period in lung adenocarcinoma patients. Detailed Description of the Invention

[0012] Definitions As used herein, a "subject" may be a mammal, preferably a human. The subject may be suffering from or at risk of a tumor or cancer. The subject may include subjects aged 70 years or older and subjects under 70 years. The subject may include smokers (e.g., with a BI index of 700 or higher) and non-smokers.

[0013] As used herein, "cancer" refers to a disease characterized by uncontrolled cell proliferation. Cancer cells may spread locally or throughout the body via the bloodstream or lymphatic system. Non-limiting examples of cancer include solid tumors. Non-limiting examples of cancer include hematopoietic tumors. Solid tumors also include lung cancer. As used herein, "cancer tissue" refers to tissue containing cancer. Cancer tissue may be obtained by biopsy and cancer resection. As used herein, "prognosis" may refer to the recurrence rate (or time to recurrence) and survival rate of cancer. Recurrence includes recurrence at the primary tumor and recurrence after metastasis. The recurrence rate may refer to the recurrence rate after a certain period of treatment. The certain period may be, for example, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, or 15 years, or any period longer than these.

[0014] As used herein, "lung adenocarcinoma" refers to a type of lung cancer. Lung cancer is broadly classified into small cell lung cancer and non-small cell lung cancer, and non-small cell lung cancer is broadly classified into three cancers, including lung adenocarcinoma. Non-small cell lung cancer accounts for approximately 80% of lung cancers, and lung adenocarcinoma accounts for approximately 60% of non-small cell lung cancers.

[0015] As used herein, "gene expression" or similar expressions refers to both the expression of messenger RNA (mRNA) from a gene present in the genome of a cell and the expression of a protein. mRNA can be detected by extracting total RNA from a cell using methods well known to those skilled in the art, for example, by synthesizing first-strand cDNA using a poly(A) sequence inherent in mRNA, followed by amplification (e.g., polymerase chain reaction). Protein can be detected using an antibody (e.g., a polyclonal or monoclonal antibody) that specifically binds to the protein.

[0016] As used herein, "positive" in the context of gene expression in cells means that mRNA or protein is detected at a detectable level, unless otherwise specified. Furthermore, "negative" means that mRNA or protein is not detected at a detectable level, unless otherwise specified. In order to clarify the classification of "positive" and "negative" in the context of gene expression in tissues, a threshold is set, and an expression level equal to or greater than the threshold is designated as "positive," while an expression level below the threshold is designated as "negative." Thus, in this specification, the criteria for determining "positive" gene expression at the cellular level and "positive" gene expression at the tissue level are different.

[0017] As used herein, expression level refers to the amount of mRNA or protein expressed in a tissue or a certain cell population. mRNA expression level can be quantified using various methods for quantifying mRNA, such as quantitative PCR, known to those skilled in the art. Protein quantification can be performed using methods known to those skilled in the art, such as immunohistochemical staining (IHC). In IHC, an antibody binds to a protein in a tissue section and can be colored with a dye. The intensity of the color corresponds to the amount of protein expression. Therefore, the amount of protein expression can be quantified based on the intensity of the color. Furthermore, in IHC, the amount of protein expression can be quantified based on the number or percentage of expressing cells, rather than the intensity of the color. Whether the amount of protein expression is quantified based on the intensity of the color or the number or percentage of expressing cells can be selected according to the situation and purpose.

[0018] As used herein, "SGLT" refers to a sodium-dependent glucose transporter that functions as a cotransporter of sodium and glucose. SGLTs include SGLT1, SGLT2, and SGLT3. SGLT1 is expressed in the renal tubules, intestine, and myocardium, while SGLT2 is expressed exclusively in the proximal tubules of the kidney. The proximal tubules extract glucose from the blood, take in what is needed, and excrete what is not needed as urine. The proximal tubules reabsorb excreted glucose and take it back into the blood. It is believed that 90% of the glucose reabsorbed here is by SGLT2, and the remaining 10% is by SGLT1.

[0019] Human SGLT1 is known to exist on a region of human chromosome 22 (22q12.3; NC_000022.11; 32043050..32113029), located between RPS17P16 and AP1B1P1. The human SGLT1 protein may have, for example, the amino acid sequence registered under GenBank accession number AAB59448.1 or a corresponding amino acid sequence. The human SGLT1 protein may have a mutation selected from the group consisting of insertion, deletion, addition, and substitution of one to several amino acids. The human SGLT1 protein may have 80% or more, 85% or more, 90% or more, or 95% or more amino acid sequence identity with the amino acid sequence registered under GenBank accession number AAB59448.1. The human SGLT1 protein may retain its function as a sodium-dependent glucose transporter.

[0020] Human SGLT2 is known to exist on a region of human chromosome 16 (16p11.2; NC_000016.10; specifically, 31482535..31490769), located between TGFB1T1 and RUSF1. The human SGLT2 protein is encoded by this chromosomal region and may have, for example, the amino acid sequence registered under NCBI Reference Sequence: NP_003032.1 or a corresponding amino acid sequence. The human SGLT2 protein may have a mutation selected from the group consisting of insertion, deletion, addition, and substitution of one to several amino acids. The human SGLT2 protein may have 80% or more, 85% or more, 90% or more, or 95% or more amino acid sequence identity with the amino acid sequence registered under GenBank Accession Number: AAB59448.1. The human SGLT2 protein may retain its function as a sodium-dependent glucose transporter.

[0021] As used herein, "diabetes" refers to a disease characterized by persistently high blood glucose levels. Specifically, diabetes can be diagnosed based on the following criteria: fasting blood glucose ≥ 126 mg / dL, HbA1c ≥ 6.5%, and a 2-hour oral glucose tolerance test (75 g OGTT) of ≥ 200 mg / dL. Diabetes is broadly classified into type 1 diabetes and type 2 diabetes. Type 1 diabetes is a disease induced by destruction of β cells, which are insulin-producing cells in the pancreas, resulting in insufficient insulin secretion, which regulates blood glucose. Type 2 diabetes is a disease induced by decreased insulin secretion from β cells, decreased responsiveness of glucose-uptake cells to insulin, or decreased glucose uptake ability into muscle and adipose tissue. Various medicines have been developed for diabetes, and SGLT2 inhibitors (e.g., ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, canagliflozin, and empagliflozin), which are responsible for the reabsorption of glucose into the blood in the proximal tubule, are considered promising for the treatment of diabetes.

[0022] <Method of Predicting Prognosis of the Present Invention (SGLT1)> (A) According to the present invention, there is provided a method of predicting the prognosis of a cancer patient, the method comprising a detection step of detecting the expression of SGLT1 in cancer tissue obtained from the cancer patient.

[0023] In the above (A), if SGLT1 is negative in the cancer tissue, it can be predicted that the prognosis is poor or there is a possibility of it (or it indicates a poor prognosis or the possibility of a poor prognosis). In the above (A), if SGLT1 is positive in the cancer tissue, it can be predicted that the prognosis is good or there is a possibility of it (or it indicates a good prognosis or the possibility of a good prognosis). In the above (A), if SGLT1 is negative in the cancer tissue, it can be predicted that the prognosis is poor or there is a possibility of it (or it indicates a poor prognosis or the possibility of a poor prognosis), and if SGLT1 is positive in the cancer tissue, it can be predicted that the prognosis is good or there is a possibility of it (or it indicates a good prognosis or the possibility of a good prognosis).

[0024] In one aspect, SGLT1 positivity or negativity can be determined based on the amount of SGLT1 in a tissue (or a section or cell lysate thereof). In one aspect, detection can be performed by quantifying mRNA encoding SGLT1. Quantification can be performed by quantitative methods well known to those skilled in the art, such as quantitative PCR, next-generation sequencing, or methods using microarrays. In another aspect, detection can be performed using an antibody that binds to SGLT1 (anti-SGLT1 antibody). Under conditions in which a complex between the SGLT1 protein and the antibody is formed, the tissue (or a section or cell lysate thereof) is contacted with the antibody that binds to SGLT1, and upon formation of the complex, the SGLT1 protein is detected. Detection can be performed by methods well known to those skilled in the art, such as Western blotting and protein array methods. Based on the amount detected, the cancer tissue can be determined to be SGLT1 positivity or negativity. In a preferred aspect, SGLT1 positivity or negativity in a cancer tissue can be confirmed by immunohistochemical staining.

[0025] The first predetermined value can be equal to or less than the maximum value, the third quartile value, the mean value, or the median value of the SGLT1 expression level in a cancer patient group with a good prognosis. The first predetermined value can be equal to or greater than the minimum value, the first quartile value, the mean value, or the median value of the SGLT1 expression level in a cancer patient group with a poor prognosis. The first predetermined value can be equal to or less than the maximum value, the third quartile value, the mean value, or the median value of the SGLT1 expression level in a cancer patient group with a good prognosis, and equal to or greater than the minimum value, the first quartile value, the mean value, or the median value of the SGLT1 expression level in a cancer patient group with a poor prognosis. In this case, whether the prognosis is good or bad can be determined by a doctor. Whether the prognosis is good or bad can be determined, for example, by the length of recurrence-free survival or the length of survival time. For example, patients whose recurrence-free survival period after cancer resection is 1,000 hours or more, 1,100 hours or more, 1,200 hours or more, 1,300 hours or more, 1,400 hours or more, 1,500 hours or more, 1,600 hours or more, 1,700 hours or more, 1,800 hours or more, 1,900 hours or more, 2,000 hours or more, 2,100 hours or more, 2,200 hours or more, 2,300 hours or more, 2,400 hours or more, 2,500 hours or more, 2,600 hours or more, 2,700 hours or more, 2,800 hours or more, 2,900 hours or more, or 3,000 hours or more can be determined to have a good prognosis, and patients whose prognosis is less than this (patients who are not determined to have a good prognosis) can be determined to have a poor prognosis. Alternatively, for example, patients whose survival time after cancer resection is 1,000 hours or more, 1,100 hours or more, 1,200 hours or more, 1,300 hours or more, 1,400 hours or more, 1,500 hours or more, 1,600 hours or more, 1,700 hours or more, 1,800 hours or more, 1,900 hours or more, 2,000 hours or more, 2,100 hours or more, 2,200 hours or more, 2,300 hours or more, 2,400 hours or more, 2,500 hours or more, 2,600 hours or more, 2,700 hours or more, 2,800 hours or more, 2,900 hours or more, or 3,000 hours or more can be determined to have a good prognosis, and patients whose survival time is less than that (patients not determined to have a good prognosis) can be determined to have a poor prognosis.

[0026] In a preferred embodiment, SGLT1 positivity or negativity can be determined by the proportion of SGLT1-positive cells in cancer cells in cancer tissue.For example, when the proportion of SGLT1-positive cells is equal to or greater than a first predetermined value, it can be predicted that the cancer patient from which the cancer tissue originates will have a poor prognosis or a possibility thereof (or a poor prognosis or a possibility of a poor prognosis is indicated).For example, when the proportion of SGLT1-positive cells is less than a first predetermined value, it can be predicted that the prognosis will be good or a possibility thereof (or a good prognosis or a possibility of a good prognosis is indicated).Furthermore, when the proportion of SGLT1-positive cells is equal to or greater than a first predetermined value, it can be predicted that the cancer patient from which the cancer tissue originates will have a poor prognosis or a possibility thereof (or a poor prognosis or a possibility of a poor prognosis is indicated), and when the proportion of SGLT1-positive cells is equal to or greater than a first predetermined value, it can be predicted that the cancer patient from which the cancer tissue originates will have a poor prognosis or a possibility thereof (or a poor prognosis or a possibility of a poor prognosis is indicated).

[0027] The first predetermined value is a threshold (or cutoff value) for the proportion of SGLT1-positive cells to cancer cells. In certain aspects, the first predetermined value can be 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 11% or more, 12% or more, 13% or more, 14% or more, 15% or more, 16% or more, 17% or more, 18% or more, 19% or more, 20% or more, 21% or more, 22% or more, 23% or more, 24% or more, 25% or more, 26% or more, 27% or more, 28% or more, 29% or more, or 30% or more. The first predetermined value can be, for example, 5 to 30%, 5 to 25%, or 10 to 20%.

[0028] In a preferred embodiment, the cancer patient is a patient who has undergone cancer resection surgery.

[0029] In a preferred embodiment, the cancer is lung cancer, more preferably lung adenocarcinoma.

[0030] In a preferred embodiment, the cancer patient is a patient who has undergone cancer resection surgery, and the cancer is lung adenocarcinoma.

[0031] In a preferred embodiment, SGLT1 expression is the expression of SGLT1 protein. In a preferred embodiment, SGLT1 positivity is determined based on the proportion of SGLT1-positive cells in cancer tissue obtained from a cancer patient. In a preferred embodiment, SGLT1 positivity is determined when the proportion of SGLT1-positive cells in cancer tissue obtained from a cancer patient is equal to or greater than a first predetermined value. In a preferred embodiment, SGLT1 negativity is determined when the proportion of SGLT1-positive cells in cancer tissue obtained from a cancer patient is less than a first predetermined value.

[0032] In a preferred embodiment, the cancer is lung adenocarcinoma, and is determined to be SGLT1 positive when the proportion of SGLT1-positive cells in cancer tissue obtained from a cancer patient is equal to or greater than a first predetermined value.

[0033] <Method of Predicting Prognosis of the Present Invention (SGLT2)> (B) Another aspect of the present invention provides a method of predicting the prognosis of a cancer patient, the method comprising a detection step of detecting the expression of SGLT2 in cancer tissue obtained from the cancer patient.

[0034] In the above (B), if SGLT2 is negative in the cancer tissue, it can be predicted that the prognosis will be poor or there is a possibility of it (or it indicates a poor prognosis or the possibility of a poor prognosis). In the above (B), if SGLT2 is positive in the cancer tissue, it can be predicted that the prognosis will be good or there is a possibility of it (or it indicates a good prognosis or the possibility of a good prognosis). In the above (B), if SGLT2 is negative in the cancer tissue, it can be predicted that the prognosis will be poor or there is a possibility of it (or it indicates a poor prognosis or the possibility of a poor prognosis), and if SGLT2 is positive in the cancer tissue, it can be predicted that the prognosis will be good or there is a possibility of it (or it indicates a good prognosis or the possibility of a good prognosis).

[0035] In one aspect, SGLT2 positivity or negativity can be determined based on the amount of SGLT2 in a tissue (or a section or cell lysate thereof). In one aspect, detection can be performed by quantifying mRNA encoding SGLT2. Quantification can be performed by quantitative methods well known to those skilled in the art, such as quantitative PCR, next-generation sequencing, or microarray methods. In another aspect, detection can be performed using an antibody that binds to SGLT2 (anti-SGLT2 antibody). Under conditions that allow a complex between the SGLT2 protein and the antibody to form, the tissue (or a section or cell lysate thereof) is contacted with the antibody, and upon formation of the complex, the SGLT2 protein is detected. Detection can be performed by methods well known to those skilled in the art, such as Western blotting and protein array methods. Based on the amount detected, the cancer tissue can be determined to be SGLT2 positivity or negativity. In a preferred aspect, SGLT2 positivity or negativity in a cancer tissue can be confirmed by immunohistochemical staining.

[0036] The second predetermined value can be equal to or less than the maximum value, the third quartile value, the mean value, or the median value of the SGLT2 expression level in a cancer patient group with a good prognosis. The second predetermined value can be equal to or greater than the minimum value, the second quartile value, the mean value, or the median value of the SGLT2 expression level in a cancer patient group with a poor prognosis. The second predetermined value can be equal to or less than the maximum value, the third quartile value, the mean value, or the median value of the SGLT2 expression level in a cancer patient group with a good prognosis, and equal to or greater than the minimum value, the second quartile value, the mean value, or the median value of the SGLT2 expression level in a cancer patient group with a poor prognosis. In this case, whether the prognosis is good or bad can be determined by a doctor. Whether the prognosis is good or bad can be determined, for example, by the length of recurrence-free survival or the length of survival time. For example, patients whose recurrence-free survival period after cancer resection is 1,000 hours or more, 1,100 hours or more, 1,200 hours or more, 1,300 hours or more, 1,400 hours or more, 1,500 hours or more, 1,600 hours or more, 1,700 hours or more, 1,800 hours or more, 1,900 hours or more, 2,000 hours or more, 2,100 hours or more, 2,200 hours or more, 2,300 hours or more, 2,400 hours or more, 2,500 hours or more, 2,600 hours or more, 2,700 hours or more, 2,800 hours or more, 2,900 hours or more, or 3,000 hours or more can be determined to have a good prognosis, and patients whose prognosis is less than this (patients who are not determined to have a good prognosis) can be determined to have a poor prognosis. Alternatively, for example, patients whose survival time after cancer resection is 1,000 hours or more, 1,100 hours or more, 1,200 hours or more, 1,300 hours or more, 1,400 hours or more, 1,500 hours or more, 1,600 hours or more, 1,700 hours or more, 1,800 hours or more, 1,900 hours or more, 2,000 hours or more, 2,100 hours or more, 2,200 hours or more, 2,300 hours or more, 2,400 hours or more, 2,500 hours or more, 2,600 hours or more, 2,700 hours or more, 2,800 hours or more, 2,900 hours or more, or 3,000 hours or more can be determined to have a good prognosis, and patients whose survival time is less than that (patients not determined to have a good prognosis) can be determined to have a poor prognosis.

[0037] In a preferred embodiment, SGLT2 positivity or negativity can be determined by the proportion of SGLT2-positive cells in cancer cells in cancer tissue. For example, when the proportion of SGLT2-positive cells is equal to or greater than a second predetermined value, it can be predicted that the cancer patient from which the cancer tissue is derived will have a poor or likely prognosis (or a poor prognosis or a possible poor prognosis is indicated). For example, when the proportion of SGLT2-positive cells is less than a second predetermined value, it can be predicted that the prognosis will be good or a possible good prognosis (or a good prognosis or a possible good prognosis is indicated). Furthermore, when the proportion of SGLT2-positive cells is equal to or greater than a second predetermined value, it can be predicted that the cancer patient from which the cancer tissue is derived will have a poor or a possible poor prognosis (or a poor prognosis or a possible poor prognosis is indicated), and when the proportion of SGLT2-positive cells is equal to or greater than a second predetermined value, it can be predicted that the cancer patient from which the cancer tissue is derived will have a poor or a possible poor prognosis (or a poor prognosis or a possible poor prognosis is indicated).

[0038] The second predetermined value is a threshold (or cutoff value) for the proportion of SGLT2-positive cells to cancer cells. In certain aspects, the second predetermined value can be 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 11% or more, 12% or more, 13% or more, 14% or more, 15% or more, 16% or more, 17% or more, 18% or more, 19% or more, 20% or more, 21% or more, 22% or more, 23% or more, 24% or more, 25% or more, 26% or more, 27% or more, 28% or more, 29% or more, or 30% or more. The second predetermined value can be, for example, 5-30%, 5-25%, or 10-20%.

[0039] In a preferred embodiment, the cancer patient is a patient who has undergone cancer resection surgery.

[0040] In a preferred embodiment, the cancer is lung cancer, more preferably lung adenocarcinoma.

[0041] In a preferred embodiment, the cancer patient is a patient who has undergone cancer resection surgery, and the cancer is lung adenocarcinoma.

[0042] In a preferred embodiment, SGLT2 expression is the expression of SGLT2 protein. In a preferred embodiment, SGLT2 positivity is determined based on the proportion of SGLT2-positive cells in cancer tissue obtained from a cancer patient. In a preferred embodiment, SGLT2 positivity is determined when the proportion of SGLT2-positive cells in cancer tissue obtained from a cancer patient is equal to or greater than a second predetermined value. In a preferred embodiment, SGLT2 negativity is determined when the proportion of SGLT2-positive cells in cancer tissue obtained from a cancer patient is less than a second predetermined value.

[0043] In a preferred embodiment, the cancer is lung adenocarcinoma, and is determined to be SGLT2-positive when the proportion of SGLT2-positive cells in cancer tissue obtained from a cancer patient is equal to or greater than a second predetermined value.

[0044] <Prognosis Prediction Method of the Present Invention (SGLT1 and SGLT2)> According to the present invention, the prognosis of a cancer patient can be predicted by combining the above (A) and (B). For example, the prognosis prediction method of the present invention may include: a detection step of detecting expression of SGLT1 in cancer tissue obtained from the cancer patient; and a detection step of detecting expression of SGLT2 in cancer tissue obtained from the cancer patient.

[0045] In the method of the present invention, when SGLT1 is negative and / or SGLT2 is positive, it is possible to predict that the prognosis of the cancer patient will be poor (a poor prognosis or a likelihood of a poor prognosis is indicated). In addition, in the method of the present invention, when SGLT1 is positive and / or SGLT2 is negative, it is possible to predict that the prognosis of the cancer patient will be good (a good prognosis or a likelihood of a good prognosis is indicated). In the method of the present invention, for example, when SGLT1 is negative and SGLT2 is positive, it is possible to predict that the prognosis of the cancer patient will be poor (a poor prognosis or a likelihood of a poor prognosis is indicated), and when SGLT1 is positive and SGLT2 is negative, it is possible to predict that the prognosis of the cancer patient will be good (a good prognosis or a likelihood of a good prognosis is indicated).

[0046] The explanations of (A) and (B) in the present invention have been given above, so please refer to them and the repeated explanations will be omitted here.

[0047] In a preferred embodiment, the cancer patient is a patient who has undergone cancer resection surgery.

[0048] In a preferred embodiment, the cancer is lung cancer, more preferably lung adenocarcinoma.

[0049] In a preferred embodiment, the cancer patient is a patient who has undergone cancer resection surgery, and the cancer is lung adenocarcinoma.

[0050] In a preferred embodiment, SGLT1 expression refers to the expression of SGLT1 protein. In a preferred embodiment, SGLT1 positivity is determined based on the proportion of SGLT1-positive cells in cancer tissue obtained from a cancer patient. In a preferred embodiment, a cancer tissue obtained from a cancer patient is determined to be SGLT1-positive when the proportion of SGLT1-positive cells in the cancer tissue is equal to or greater than a first predetermined value. In a preferred embodiment, a cancer tissue obtained from a cancer patient is determined to be SGLT1-negative when the proportion of SGLT1-positive cells in the cancer tissue is less than a first predetermined value. The first predetermined value may be, for example, 5 to 30%, 5 to 25%, or 10 to 20%.

[0051] In a preferred embodiment, SGLT2 expression refers to the expression of SGLT2 protein. In a preferred embodiment, SGLT2 positivity is determined based on the proportion of SGLT2-positive cells in cancer tissue obtained from a cancer patient. In a preferred embodiment, a cancer tissue obtained from a cancer patient is determined to be SGLT2-positive when the proportion of SGLT2-positive cells in the cancer tissue is equal to or greater than a second predetermined value. In a preferred embodiment, a cancer tissue obtained from a cancer patient is determined to be SGLT2-negative when the proportion of SGLT2-positive cells in the cancer tissue is less than a second predetermined value. The second predetermined value may be, for example, 5-30%, 5-25%, or 10-20%.

[0052] <Further Aspects of the Present Invention> The present invention provides a method for predicting the prognosis of a cancer patient, comprising: (2) predicting a good prognosis if the patient is a diabetic patient, and predicting a poor prognosis if the patient is a non-diabetic patient.

[0053] Whether a cancer patient has diabetes can be determined by a doctor's diagnosis. In one embodiment, the cancer patient may be a cancer patient who has received SGLT2 inhibitor therapy.

[0054] The present invention also provides a method for predicting the prognosis of a cancer patient, comprising: (3) predicting a good prognosis if the patient has a mutation in epidermal growth factor receptor (EGFR), and predicting a poor prognosis if the patient does not have a mutation in EGFR.

[0055] The EGFR mutation in the above case may be an EGFR driver mutation. An EGFR driver mutation is a mutation that enhances EGFR activity and causes cancer. EGFR is an epidermal growth factor receptor, and when it binds to epidermal growth factor (EGF), it transmits a proliferation signal to cells. Cells that receive a proliferation signal proliferate. An EGFR driver mutation induces or enhances a proliferation signal through the mutation. Examples of such EGFR driver mutations include any mutation selected from the group consisting of G719X, a deletion in exon 19 (del 19), S768I, an insertion in exon 20 (ins 20), T790M, L858R, and L861Q (where X represents any amino acid other than G). These driver mutations are found in cancer and enhance or positively activate EGFR activity. G719X, exon 19 deletion (del 19), and L858R contribute to a high response rate to EGFR tyrosine kinase inhibitors (EGFR-TKIs), while T790M and exon 20 insertions are associated with therapeutic resistance to EGFR-TKIs. Examples of exon 19 deletions (del 19) include, but are not limited to, delE746_A750. Examples of exon 20 insertions (ins 20) include, but are not limited to, V769_D770insASV, D770_N771insSVD, and H773_V774insH. Examples of G719X include, but are not limited to, G719A, G719S, and G719C.

[0056] Cancer patients with driver mutations in EGFR include cancer patients who have received EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. Examples of EGFR tyrosine kinase inhibitors (EGFR-TKIs) include first-generation EGFR-TKIs such as gefitinib and erlotinib, second-generation EGFR-TKIs such as afatinib and dacomitinib, and third-generation EGFR-TKIs such as osimertinib.

[0057] The method of predicting cancer prognosis of the present invention may be a combination of any two, three, or four selected from the group consisting of (A), (B), (2), and (3). For example, the method of predicting cancer prognosis of the present invention may include (A) and (2). For example, the method of predicting cancer prognosis of the present invention may include (A) and (3). For example, the method of predicting cancer prognosis of the present invention may include (A), (2), and (3). For example, the method of predicting cancer prognosis of the present invention may include (B) and (2). For example, the method of predicting cancer prognosis of the present invention may include (B) and (3). For example, the method of predicting cancer prognosis of the present invention may include (B), (2), and (3). For example, the method of predicting cancer prognosis of the present invention may include (A), (B), and (2). For example, the method of predicting cancer prognosis of the present invention may include (A), (B), and (3). For example, the method of predicting cancer prognosis of the present invention may include (A), (B), (2), and (3) above.

[0058] Then, in each of (A), (B), (2), and (3), a prediction of whether the prognosis is good or bad can be obtained. If all predictions agree that the prognosis is good, the prognosis of the patient from whom the cancer tissue was derived is predicted to be good (or the prognosis is good or likely to be good). If all predictions agree that the prognosis is bad, the prognosis of the patient from whom the cancer tissue was derived is predicted to be bad (or the prognosis is bad or likely to be bad). If all predictions do not agree, it is possible to make no prediction, or to predict a good or bad prognosis depending on the purpose. For example, for the purpose of treatment, it is possible to predict a bad prognosis and select a more efficient treatment. Even if all predictions do not agree, if the number of predictions that the prognosis is good is greater than the number of predictions that the prognosis is bad, it is possible to predict a good prognosis of the patient from whom the cancer tissue was derived (or it can be shown that the prognosis is good or likely to be good). Furthermore, even if all predictions are inconsistent, if the number of predictions of poor prognosis outnumbers the number of predictions of good prognosis, it is possible to predict that the prognosis of the patient from whom the cancer tissue originated will be poor (or it may be indicated that the prognosis will be poor or likely to be poor). When the prognosis is not predicted to be either good or bad, for example, a prediction result indicating that it cannot be said to be neither good nor bad can be returned.

[0059] The method for predicting prognosis of the present invention may be an industrially applicable invention. The method for predicting prognosis of the present invention may be an in vitro method. The method for predicting prognosis of the present invention may be a method for predicting prognosis, an auxiliary method for predicting prognosis, or a method for obtaining basic information for predicting prognosis. The method for predicting prognosis of the present invention may not include a step of diagnosis by a physician. After performing the method for predicting prognosis of the present invention, a physician can diagnose the prognosis. The method for predicting prognosis of the present invention may not include a step of diagnosing an animal (particularly a human).

[0060] Pharmaceutical Compositions of the Present Invention The present invention provides a pharmaceutical composition comprising an SGLT2 inhibitor for use in treating cancer in SGLT2-positive cancer patients. The cancer may be lung cancer, preferably lung adenocarcinoma. The cancer patient may also be a cancer patient predicted to have a good prognosis using the above-mentioned prognosis predicting method of the present invention. The cancer patient may also be a cancer patient predicted to have a poor prognosis using the above-mentioned prognosis predicting method of the present invention. The cancer patient may also be a cancer patient predicted to have neither a good nor poor prognosis using the above-mentioned prognosis predicting method of the present invention. In one embodiment, the cancer patient may be a patient with unresectable or recurrent cancer. In one embodiment, the cancer patient may be a patient who has undergone cancer resection surgery. In one embodiment, the cancer patient is suffering from diabetes and cancer. In one embodiment, the cancer patient has a driver mutation in EGFR. In one embodiment, the cancer patient has a driver mutation in EGFR and is suffering from diabetes and cancer. In one embodiment, the cancer patient does not have a driver mutation in EGFR and is suffering from diabetes and cancer. In a preferred embodiment of the present invention, the pharmaceutical composition of the present invention can be administered in combination with an insulin sensitizer to a patient with lung adenocarcinoma and diabetes mellitus who has been treated with an insulin sensitizer or is scheduled to be treated with an insulin sensitizer.

[0061] According to the present invention, an SGLT2-positive cancer patient may be a patient who has undergone cancer resection surgery. According to the present invention, an SGLT2-positive cancer patient may be a cancer patient in which the proportion of SGLT2-positive cells among cancer cells in immunohistochemical staining of the cancer tissue is equal to or greater than a second predetermined value. The second predetermined value may be, for example, 5 to 30%, 5 to 25%, or 10 to 20%.

[0062] According to the present invention, an SGLT2-positive cancer patient may be SGLT1-positive. According to the present invention, an SGLT2-positive cancer patient may be SGLT1-negative. According to the present invention, an SGLT2-positive cancer patient may be a cancer patient in which the proportion of SGLT2-positive cells among cancer cells in immunohistochemical staining of the cancer tissue is equal to or greater than a first predetermined value. The first predetermined value may be, for example, 5 to 30%, 5 to 25%, or 10 to 20%.

[0063] The present invention provides an SGLT2 inhibitor for use in treating cancer. The present invention provides use of an SGLT2 inhibitor in the manufacture of a medicament for treating cancer. The present invention provides a method for treating cancer in a subject having cancer, comprising administering a therapeutically effective amount of an SGLT2 inhibitor to the patient. The patient may be a subject predicted to have a good prognosis in the prognosis prediction method of the present invention. The patient may be a subject predicted to have a poor prognosis in the prognosis prediction method of the present invention. The patient may be a subject predicted to have neither a good nor a poor prognosis in the prognosis prediction method of the present invention. According to the present invention, for example, by administering an SGLT2 inhibitor to a patient with a good prognosis, patient pain caused by futile treatment can be avoided. According to the present invention, for example, by administering an SGLT2 inhibitor to a patient with a poor prognosis, treatment can be performed only on subjects who can tolerate the SGLT2 inhibitor, even if it has strong side effects. Alternatively, an increased dose of an SGLT2 inhibitor can be administered to a patient with a poor prognosis. According to the present invention, there is provided use of an SGLT2 inhibitor in the manufacture of a medicament for treating cancer. The SGLT2 inhibitor may be any of the SGLT2 inhibitors exemplified above or a pharmaceutical product containing the SGLT2 inhibitor.

[0064] The SGLT2 inhibitor may be included in a pharmaceutical composition, which may include the SGLT2 inhibitor and a pharmaceutically acceptable carrier, diluent, and / or excipient. The pharmaceutical composition may be formulated for oral or parenteral administration.

[0065] The present invention provides a pharmaceutical composition for treating a patient with lung adenocarcinoma and diabetes, comprising an insulin sensitizer. The present invention also provides the use of an insulin sensitizer in the manufacture of a medicament for treating a patient with lung adenocarcinoma and diabetes. The present invention also provides a method for treating a patient with lung adenocarcinoma and diabetes, comprising administering a therapeutically effective amount of an insulin sensitizer to the patient. In some embodiments, the therapeutically effective amount of an insulin sensitizer improves the patient's prognosis (e.g., survival rate and recurrence-free survival). Examples of insulin sensitizers include biguanides and PPARγ agonists (e.g., thiazolidinediones). Examples of biguanides include metformin, buformin, and phenformin. Examples of thiazolidine drugs include isaglitazone, (S)-((3,4-dihydro-2-(phenyl-methyl)-2H-1-benzopyran-6-yl)methyl-thiazolidine-2,4-dione (englitazone), 5-{[4-(3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl)-phenyl]-methyl}-thiazolidine-2,4-dione (darglitazone), 5-{[4-(1-methyl-cyclohexyl)methoxy]-phenyl}methyl)-thiazolidine-2,4-dione (ciglitazone), 5-{[4-(2-(1-indolyl)ethoxy)phenyl]methyl}-thiazolidine-2,4-dione (DRF2189), 5-{4 -[2-(5-methyl-2-phenyl-4-oxazolyl)-ethoxy]benzyl}-thiazolidine-2,4-dione (BM-13.1246), 5-(2-naphthylsulfonyl)-thiazolidine-2,4-dione (AY-31637), bis{4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl}methane (YM268), 5-{4-[2-(5-methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy]benzyl}-thiazolidine-2,4-dione (AD-5075), 5-[4-(1-phenyl-1-cyclopropanecarbonylamino)-benzyl]-thiazolidine-2,4-dione (DN-108), 5-{[4-(2-(2,3-dihydroindol-1-yl)ethoxy)phenyl]methyl}-thiazolidine-2,4-dione, 5-[3-(4-chloro-phenyl)]-2-propynyl]-5-phenylsulfonyl)thiazolidine-2,4-dione, 5-[3-(4-chlorophenyl)]-2-propynyl]-5-(4-fluorophenyl-sulfonyl)thiazolidine-2,4-dione, 5-{[4-(2-(methyl-2-pyridinyl-amino)ethoxy)phenyl]methyl}-thiazolidine-2,4-dione (rosiglitazone), 5-{[4-(2-(5-ethyl-2-pyridyl)ethoxy)phenyl]-methyl}-thiazolidine-2,4-dione (pioglitazone), Examples include 5-{[4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)-phenyl]-methyl}-thiazolidine-2,4-dione (troglitazone), 5-[6-(2-fluoro-benzyloxy)naphthalen-2-ylmethyl]-thiazolidine-2,4-dione (MCC-555), 5-{[2-(2-naphthyl)-benzoxazol-5-yl]-methyl}thiazolidine-2,4-dione (T-174), and 5-(2,4-dioxothiazolidin-5-ylmethyl)-2-methoxy-N-(4-trifluoromethyl-benzyl)benzamide (KRP297). In a preferred embodiment, the thiazolidine drug may include, for example, pioglitazone, rosiglitazone, or troglitazone.

[0066] The present invention provides a combination product containing an SGLT2 inhibitor and an insulin sensitizer for use in treating subjects with diabetes and lung adenocarcinoma. In the combination product, the SGLT2 inhibitor and the insulin sensitizer may be contained separately or as a mixture. That is, the combination product may contain a container containing the SGLT2 inhibitor and a container containing the insulin sensitizer, or may contain a container containing the SGLT2 inhibitor and the insulin sensitizer. A combination product containing a first container containing the SGLT2 inhibitor and a second container containing the insulin sensitizer may have packaging containing the first and second containers. The combination product may further contain instructions (e.g., package inserts) for administering the SGLT2 inhibitor and the insulin sensitizer. The combination product is a pharmaceutical product and is used for pharmaceutical purposes.

[0067] The pharmaceutical composition of the present invention may be used in combination with other anticancer drugs, thereby reducing the amount of the other anticancer drugs used and enabling safer cancer treatment.

[0068] Example 1: Analysis of SGLT1 and SGLT2 expression using lung adenocarcinoma biopsies In this example, the expression of SGLT1 and SGLT2 was examined in biopsies or resected tissues obtained from lung adenocarcinoma patients.

[0069] The specimens used were 102 lung adenocarcinoma cases that were available for immunostaining and clinicopathological examination out of 182 cases resected at a municipal general hospital between October 2010 and September 2017. The mean age of the patients was 70.5 years, and the patients ranged in age from 43 to 89 years. Patient details are as shown in Table 1 below.

[0070]

[0071] In Table 1, DM stands for diabetes, CEA stands for CEA marker expression, and EGFR stands for epidermal growth factor receptor. The EGFR mutations are any of the following driver mutations: G719X, a deletion in exon 19 (del19), S768I, an insertion in exon 20, T790M, L858R, and L861Q.

[0072] Tissue sections were prepared from biopsies or tissue donations according to standard procedures and subjected to immunohistochemical staining. Anti-SGLT1 antibody (Abcam; 1 / 500) and anti-SGLT2 antibody (Abcam; 1 / 180) were used as primary antibodies. The rabbit anti-mouse IgG antibody included in the BOND Polymer Refine Detection (Leica Biosystems) kit was used as the secondary antibody according to the manufacturer's instructions. Subsequently, staining was performed using horseradish peroxidase (HRP)-conjugated anti-rabbit IgG antibody. Staining was performed using an automated immunostainer, BOND-MAX (Leica Biosystems). The stained images were evaluated using virtual slides (device used: Nano Zoomer-XR (Hamamatsu Photonics KK), conditions: 20x mode, single layer).

[0073] The expression of SGLT1 and SGLT2 was evaluated using two cutoffs: a cutoff (10% cutoff) that considered expression in 10% or more of the cells in the cancer cell population in the section as positive, and a cutoff (20% cutoff) that considered expression in 20% or more of the cells in the cancer cell population in the section as positive.

[0074] As shown in Figure 1, when comparing stages I and II, the recurrence-free survival period tended to be longer in stage I than in stage II. Furthermore, when comparing stages I and II with stages III and IV, as shown in Figure 2, the recurrence-free survival period tended to be longer in early-stage cancer (stages I and II) than in stages III and IV. Furthermore, when comparing survival curves between stage I and stages II to IV, as shown in Figure 3, it was shown that more patients in stage I survived longer than in other stages. The same was true when comparing stages I and II with stages III and IV, showing that more patients in early-stage cancer (stages I and II) survived longer than in stages III and IV.

[0075] Next, we investigated the relationship between SGLT1 and SGLT2 expression and recurrence-free survival or survival curves for patients with stage I to IV cancer or early-stage cancer (stage I and II; a total of 79 patients). The results are shown in Figures 5 to 22. The results shown in Figures 5 to 22 are also shown in Table 2.

[0076]

[0077] As shown in Figures 5 to 22, the group with higher SGLT1 expression tended to be less likely to recur and to have a longer survival period than the group with lower SGLT1 expression. In contrast, the group with lower SGLT2 expression tended to be less likely to recur and to have a longer survival period than the group with higher SGLT2 expression.

[0078] In Figure 5, in 102 cases of lung adenocarcinoma, higher SGLT1 expression tended to result in longer recurrence-free survival. In Figures 6 and 7, lower SGLT2 expression tended to result in longer recurrence-free survival. In Figure 8, higher SGLT1 expression tended to result in a higher patient survival rate. In Figure 11, higher SGLT1 expression in stage I lung adenocarcinoma tended to result in longer recurrence-free survival. In Figures 12 and 13, lower SGLT2 expression in stage I lung adenocarcinoma tended to result in longer recurrence-free survival. As shown in Figure 14, higher SGLT1 expression in stage I lung adenocarcinoma tended to result in a higher survival rate. As shown in Figure 17, higher SGLT1 expression tended to result in longer recurrence-free survival in early-stage cancer (stages I and II). As shown in Figures 18 and 19, lower SGLT2 expression tended to result in longer recurrence-free survival in early-stage cancer (stages I and II). As shown in Figure 20, a tendency was observed in stage I lung adenocarcinoma where the higher the expression of SGLT1, the higher the survival rate.

[0079] Furthermore, age (comparison between those aged 70 or over and those under 70), history of diabetes (comparison between those with and without DM), high and low CEA levels), and EGFR mutation (comparison between those with and without EGFR mutation) were also analyzed. The results are shown in Figures 23 to 44.

[0080] As shown in Figure 23, patients aged 70 years or older tended to have a higher recurrence rate than patients under 70 years old. As shown in Figure 24, patients under 70 years old who were SGLT1 positive tended to have no recurrence (less likely to recur), while patients over 70 years old who were SGLT1 negative tended to have a higher recurrence rate. As shown in Figure 25, patients under 70 years old who were SGLT2 negative tended to have a lower recurrence rate, while patients over 70 years old who were SGLT2 positive tended to have a higher recurrence rate. As shown in Figure 26, no deaths were observed in patients under 70 years old who were SGLT1 positive, while patients over 70 years old who were SGLT1 negative tended to have a poor prognosis. As shown in Figure 27, diabetic patients (DM) tended to have a lower recurrence rate than non-diabetic patients. As shown in Figure 28, diabetic patients who were SGLT1 positive tended to have no recurrence (less likely to recur), while non-diabetic patients who were SGLT1 negative tended to have a higher recurrence rate. As shown in Figure 29, diabetic patients who were SGLT2 negative tended to have no recurrence (less likely to recur). As shown in Figure 30, diabetic patients tended to have a better prognosis than non-diabetic patients. As shown in Figure 31, non-diabetic patients who were SGLT1 negative tended to have a poor prognosis. As shown in Figure 32, when SGLT1 was positive and CEA levels were low (less than 5.0 ng / ml), recurrence did not occur (less likely to recur), while when SGLT1 was negative and CEA levels were high (5.0 ng / ml or higher), recurrence tended to occur. As shown in Figures 33 and 34, when SGLT2 was negative and CEA levels were low, recurrence was less likely, while when SGLT2 was positive and CEA levels were high, recurrence tended to occur more. As shown in Figure 35, no deaths were observed when SGLT1 was positive and CEA was low, while a tendency for poor prognosis was observed when SGLT1 was negative and CEA levels were high. As shown in Figures 38 and 39, cases where SGLT1 was positive and SGLT2 was negative tended to not recur (to be less likely to recur), while cases where SGLT1 was negative and SGLT2 was positive tended to be more likely to recur. As shown in Figure 44, cases with EGFR mutations tended to be less likely to recur than cases without mutations.The EGFR mutations referred to here were driver mutations, including G719X, a deletion in exon 19 (del19), S768I, an insertion in exon 20, T790M, L858R, and L861Q. As shown in Figure 45, diabetic patients tended to have a longer recurrence-free survival period than non-diabetic patients. As shown in Figure 46, diabetic patients tended to have a better survival rate than non-diabetic patients. As shown in Figure 47, in early-stage cancers (stage I and II), diabetic patients tended to have a longer recurrence-free survival period than non-diabetic patients. As shown in Figure 48, in early-stage cancers (stage I and II), diabetic patients tended to have a better survival rate than non-diabetic patients.

[0081] As described above, SGLT1 correlates with both recurrence-free survival and survival rate, and the group with higher SGLT1 expression showed a tendency for longer recurrence-free survival and higher survival rate than the group with lower SGLT1 expression. SGLT2 also correlates with recurrence-free survival, and the group with lower SGLT2 expression showed a tendency for longer recurrence-free survival than the group with higher SGLT2 expression. Furthermore, the older group showed a tendency for worse prognosis. Furthermore, diabetic patients tended to be less likely to recur and have a better prognosis than non-diabetic patients. Furthermore, EGFR mutation cases showed a tendency for a better prognosis than cases without mutations. Recurrence included primary recurrence and metastasis, and a common trend was observed between primary recurrence and metastasis.

[0082] No correlation was observed between prognosis and gender. Smoking (a BI index of 700 or higher and smoking prior to hospitalization) also had a negative effect on prognosis, with no recurrence observed in SGLT1-positive non-smoking patients, while SGLT1-negative smokers tended to recur easily. SGLT2-negative non-smoking patients were less likely to recur, while SGLT2-positive smokers always recurred.

[0083] It has been suggested that the reason why diabetic patients have a better prognosis than non-diabetic patients may be because some diabetic patients are receiving SGLT2 inhibitor therapy, metformin therapy, DPP-4 inhibitor therapy, etc. It has also been suggested that the reason why EGFR mutation cases have a better prognosis than non-mutation cases may be because EGFR mutation cases are receiving EGFR-targeted therapy.

[0084] The relationship between diabetes and the prognosis of lung cancer or lung adenocarcinoma patients was investigated. The relationship between the survival rate of 1,798 lung cancer cases and the presence or absence of diabetes was shown in Figure 49. Lung cancer patients with diabetes mellitus (DM) had a worse prognosis than lung cancer patients without DM. The relationship between the recurrence-free survival period and the presence or absence of diabetes for the same 1,798 lung cancer cases was shown in Figure 50. The results showed no significant difference in recurrence-free survival period depending on the presence or absence of DM, but lung cancer patients with DM tended to have a worse prognosis than lung cancer patients without DM.

[0085] The relationship between survival rate and type of diabetes treatment was investigated for 1,482 patients with non-small cell lung cancer. Analysis of these 1,482 patients revealed no significant difference in recurrence-free survival between those with and without DM. However, patients with DM tended to have a worse prognosis than those without DM (see Figure 51). The relationship between survival rate and type of diabetes treatment was also investigated for patients with non-small cell lung cancer who underwent surgical resection (388 cases). The results, shown in Figure 52, indicated that among patients with non-small cell lung cancer who underwent surgical treatment, patients without diabetes (DM) had a better prognosis than those with DM.

[0086] Next, we examined the relationship between recurrence-free survival and type of diabetes treatment in 194 patients with lung adenocarcinoma. The 194 patients were divided into three groups based on the type of treatment: group A (n = 12), group B (n = 3), and no treatment group (n = 173). Group A was treated with insulin secretagogues, and group B was treated with insulin sensitizers. Patients in group A received insulin, Amaryl, or glimepiride. Patients in group B received buformin (Givetose), metformin (Melvin), pioglitazone (Actos), or pioglitazone / alogliptin (Lyovel). Three patients in group A also received insulin sensitizers. One patient in group B also received a glucose absorption / excretion modulator.

[0087] The results are shown in Figure 53. Group B, which received treatment with an insulin sensitizer, had the best prognosis. In contrast, Group A, which received treatment with an insulin secretagogue, showed no difference in prognosis compared to the untreated group. Compared with patients without diabetes, patients with lung adenocarcinoma had a better prognosis, with Group B, which received treatment with an insulin sensitizer, showing the best prognosis.

[0088] These results showed that lung adenocarcinoma patients with diabetes had a good prognosis, and that patients treated with insulin sensitizers had an even better prognosis. This result was in contrast to the results for all lung cancer patients and all non-small cell lung cancer patients. The reason for the better prognosis in Group B is thought to be that lung adenocarcinoma patients have impaired insulin function, which causes blood sugar levels to rise and provides energy to the cancer. However, improving insulin function and lowering blood sugar cuts off the energy supply to the cancer.

Claims

1. A pharmaceutical composition for use in treating a subject with lung adenocarcinoma, comprising an SGLT2 inhibitor or an insulin sensitizer.

2. The pharmaceutical composition described in claim 1, wherein the subject is a diabetic patient.

3. 3. The pharmaceutical composition according to claim 1, wherein the insulin sensitizer is one or more selected from the group consisting of biguanides and thiazolidinediones.

4. 2. The pharmaceutical composition of claim 1, comprising an SGLT2 inhibitor for use in treating lung adenocarcinoma in SGLT2-positive patients.

5. The pharmaceutical composition according to claim 3, wherein the patient is a diabetic SGLT2 positive patient.

6. The pharmaceutical composition according to claim 3, wherein the patient is an SGLT2-positive non-diabetic patient.